News > tag

5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry.
(more…)

Key findings of the study:

• Using PET scans instead of SPECT scans resulted in increased rates of diagnosis of severe obstructive coronary artery disease from 70 percent to 79 percent.
• PET scans were associated with a lower incidence of invasive catheterization without identification of severe coronary artery disease (43% vs 55%). (more…)

^99mTc-sestamibi CZT-SPECT is technically feasible and can provide similar result to 15O-water PET for detecting impaired myocardial flow reserve and abnormal fractional flow reserve in patients with coronary artery disease. This study highlights the diagnostic value of using ^99mTc -sestamibi for patients with coronary artery disease.

The WATERDAY study: Denis Agostini & Vincent (more…)

Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target.¬†This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting Œ±vŒ≤3 integrin, occurs in¬†prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. (more…)